Home › Research › Biomarkers
AD-related plasma biomarkers in centenarians: links to cognition and neuropathology
Linda M C Lorenz, Susan K Rohde, Maruelle C Luimes, Annemieke J M Rozemuller, Netherlands Brain Bank, Marc Hulsman, Marieke J I Graat, Myke E van der Hoorn et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-12
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Cognition ranged from high to early cognitive decline (median Mini-Mental State Examination [MMSE] score = 26). Lower plasma Aβ40 and Aβ42 are associated with poorer executive functioning, attention/processing speed, and higher Aβ neuropathology. Elevated plasma NfL and GFAP are associated with poorer executive functioning, slower processing speed, and Aβ and tau neuropathology. Higher plasma pTau-181 and the pTau-181/Aβ42 ratio are associated with Aβ and tau neuropathology, but not with cognitive performance. The Aβ42/40 ratio was uninformative. Plasma Aβ, NfL, and GFAP detected neuropathology and early cognitive decline in centenarians; plasma pTau-181 and the pTau-181/Aβ42 ratio primarily report more advanced neuropathology. HIGHLIGHTS: Lower plasma Aβ40 and Aβ42 concentrations are associated with poorer executive functioning and higher Aβ neuropathology, and thus may detect early cognitive decline in centenarians. Higher plasma pTau-181 concentrations and the pTau-181/Aβ42 ratio are strongly associated with Aβ and tau neuropathology; however, they are not associated with cognitive performance. Higher NfL concentrations are associated with higher Aβ and tau neuropathology. Higher plasma NfL and GFAP concentrations are associated with poorer attention and processing speed and may detect early cognitive decline in centenarians.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lorenz, L. M. C., Rohde, S. K., Luimes, M. C., Rozemuller, A. J. M., Bank, N. B., Hulsman, M., et al. (2025). AD-related plasma biomarkers in centenarians: links to cognition and neuropathology. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70969
Vancouver
Lorenz LMC, Rohde SK, Luimes MC, Rozemuller AJM, Bank NB, Hulsman M, et al. AD-related plasma biomarkers in centenarians: links to cognition and neuropathology. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70969. PMID: 41416584.
BibTeX
@article{lorenz2025-41416584,
author = {Lorenz, Linda M C and Rohde, Susan K and Luimes, Maruelle C and Rozemuller, Annemieke J M and Bank, Netherlands Brain and Hulsman, Marc and Graat, Marieke J I and van der Hoorn, Myke E and others},
title = {{AD-related plasma biomarkers in centenarians: links to cognition and neuropathology}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70969},
pmid = {41416584},
url = {https://doi.org/10.1002/alz.70969}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Cognition ranged from high to early cognitive decline (median Mini-Mental State Examination [MMSE] score = 26).
- Lower plasma Aβ40 and Aβ42 are associated with poorer executive functioning, attention/processing speed, and higher Aβ neuropathology.
- Elevated plasma NfL and GFAP are associated with poorer executive functioning, slower processing speed, and Aβ and tau neuropathology.
- Higher plasma pTau-181 and the pTau-181/Aβ42 ratio are associated with Aβ and tau neuropathology, but not with cognitive performance.
- Plasma Aβ, NfL, and GFAP detected neuropathology and early cognitive decline in centenarians; plasma pTau-181 and the pTau-181/Aβ42 ratio primarily report more advanced neuropathology.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants60
- Evidence strengthModerate
How this study scored 70/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 39 of the 56 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 60 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41416584) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 39 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 39 of the 56 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
693 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 693 tagged studies.